2022-501327-25-00CompletedPhase 4
Comparative Bioavailability of Lenvatinib 10 mg Capsules in Healthy Subjects
Bluepharma Industria Farmaceutica S.A.1 site in 1 country36 target enrollmentStarted: March 3, 2023Last updated:
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Enrollment
- 36
- Locations
- 1
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Matilde Melo
Scientific
Bluepharma Industria Farmaceutica S.A.
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 4
Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fed Conditions2024-512912-23-00Bluepharma Industria Farmaceutica S.A.30
Suspended
Phase 4
Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fasting Conditions.2024-512908-19-00Bluepharma Industria Farmaceutica S.A.30
Unknown
Phase 1
Relative Bioavailability of the Baricitinib (LY3009104) Commercial Tablet Compared to the Phase 2 Tablets and the Effect of Food on the Bioavailability of the Commercial Tablet in Healthy Japanese SubjectsHealthy VolunteersJPRN-jRCT2080222636Eli Lilly Japan K.K.
Completed
Phase 4
Comparative Bioavailability of Cabozantinib Film-Coated Tablets in Healthy Participants Under Fasting Conditions2024-511647-25-00Bluepharma Industria Farmaceutica S.A.15
Completed
Phase 1
A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult ParticipantsHealthy VolunteersNCT04898101Acerta Pharma BV14